{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-290779","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.716993+00:00","generated_at":"2026-06-07T16:03:29.000859+00:00","sec_items":["1.01","2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vanda acquires U.S. and Canadian rights to PONVORY for $100M upfront","bullets":["Acquired exclusive U.S. and Canadian rights to PONVORY (ponesimod), a once-daily oral S1P1R modulator for relapsing multiple sclerosis.","Upfront cash payment of $100 million to Janssen (Johnson & Johnson); transaction closed December 7, 2023.","Janssen will continue operations under a transitional services agreement while Vanda assumes regulatory and supply responsibility.","Vanda CEO highlights PONVORY as a versatile immune-response modifier with potential application in autoimmune disorders beyond MS."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-290779","json":"https://secwatch.observer/filing/0001193125-23-290779.json","markdown":"https://secwatch.observer/filing/0001193125-23-290779.md","text":"https://secwatch.observer/filing/0001193125-23-290779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000119312523290779/0001193125-23-290779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000119312523290779/d635973d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:03:29.000859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78341aa2853387017f320167295a8d554893028d","claim":"Vanda Pharmaceuticals Inc. completed an acquisition involving Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company for $100 million (closed 2023-12-07).","evidence_excerpt":"Vanda made an upfront payment of $100 million to Janssen as consideration for the Purchased Assets.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312523290779/0001193125-23-290779-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company"},{"label":"Consideration","value":"$100 million"},{"label":"Closing","value":"2023-12-07"}],"fact_type":"ma_transaction"},{"claim_id":"df7b44f347c5179d150356e4a815126542af7d42","claim":"Vanda Pharmaceuticals Inc. entered into Purchase Agreement with Actelion Pharmaceuticals Ltd. (Janssen, a Johnson & Johnson Company) valued at $100 million (effective 2023-12-07).","evidence_excerpt":"On December 7, 2023, Vanda Pharmaceuticals Inc. (“Vanda”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Actelion Pharmaceuticals Ltd. (“Janssen”), a Johnson & Johnson Company, pursuant to which Vanda acquired from Janssen the U.S. and Canadian rights for PONVORY ® (ponesimod).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312523290779/0001193125-23-290779-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Actelion Pharmaceuticals Ltd. (Janssen, a Johnson & Johnson Company)"},{"label":"Value","value":"$100 million"},{"label":"Effective","value":"2023-12-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}